DE60331871D1 - Pharmazeutische Verbindung und Methoden zur Behandlungen von menschliche Karzinome mittels Arginin Entzug - Google Patents

Pharmazeutische Verbindung und Methoden zur Behandlungen von menschliche Karzinome mittels Arginin Entzug

Info

Publication number
DE60331871D1
DE60331871D1 DE60331871T DE60331871T DE60331871D1 DE 60331871 D1 DE60331871 D1 DE 60331871D1 DE 60331871 T DE60331871 T DE 60331871T DE 60331871 T DE60331871 T DE 60331871T DE 60331871 D1 DE60331871 D1 DE 60331871D1
Authority
DE
Germany
Prior art keywords
treatment
arginine
withdrawal
methods
pharmaceutical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331871T
Other languages
English (en)
Inventor
Ning Man Cheng
Yun Chung Leung
Wai Hung Lo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Cancer Treatment Int Ltd
Bio Cancer Treatment International Ltd
Original Assignee
Bio Cancer Treatment Int Ltd
Bio Cancer Treatment International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000613&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60331871(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio Cancer Treatment Int Ltd, Bio Cancer Treatment International Ltd filed Critical Bio Cancer Treatment Int Ltd
Application granted granted Critical
Publication of DE60331871D1 publication Critical patent/DE60331871D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60331871T 2002-06-20 2003-06-20 Pharmazeutische Verbindung und Methoden zur Behandlungen von menschliche Karzinome mittels Arginin Entzug Expired - Lifetime DE60331871D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39075702P 2002-06-20 2002-06-20
PCT/CN2002/000635 WO2004001048A1 (en) 2002-06-20 2002-09-09 Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation

Publications (1)

Publication Number Publication Date
DE60331871D1 true DE60331871D1 (de) 2010-05-06

Family

ID=30000613

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60331871T Expired - Lifetime DE60331871D1 (de) 2002-06-20 2003-06-20 Pharmazeutische Verbindung und Methoden zur Behandlungen von menschliche Karzinome mittels Arginin Entzug
DE60319083T Expired - Lifetime DE60319083T2 (de) 2002-06-20 2003-06-20 Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin-entzug

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60319083T Expired - Lifetime DE60319083T2 (de) 2002-06-20 2003-06-20 Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin-entzug

Country Status (12)

Country Link
US (4) US7951366B2 (de)
EP (1) EP1517699B1 (de)
JP (2) JP5307042B2 (de)
CN (2) CN101433714A (de)
AT (2) ATE461707T1 (de)
AU (1) AU2002325782A1 (de)
DE (2) DE60331871D1 (de)
HK (3) HK1053577A2 (de)
IL (1) IL165858A (de)
MX (1) MXPA04012970A (de)
NZ (1) NZ537774A (de)
WO (1) WO2004001048A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745847A (zh) * 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US20090068166A1 (en) * 2006-03-17 2009-03-12 Ning Man Cheng Method and composition for protection against radiation
US20080138858A1 (en) * 2006-12-12 2008-06-12 Bio-Cancer Treatment International Ltd. Expression System for Recombinant Human Arginase I
WO2010023195A2 (en) * 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions and methods for treating cancer
FI3778885T3 (fi) 2008-10-31 2023-05-23 Aerase Inc Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
JP5746137B2 (ja) 2009-03-26 2015-07-08 ザ ホン コン ポリテクニック ユニバーシティ アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用
US8679479B2 (en) 2009-06-29 2014-03-25 Aerase, Inc. Methods for purifying pegylated arginase
CN103184208B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
WO2015165374A1 (en) 2014-04-29 2015-11-05 Bio-Cancer Treatment International Limited Methods and compositions for modulating the immune system with arginase i
JP2016117702A (ja) * 2014-12-22 2016-06-30 武輝 山田 ガン細胞の死滅法
CN105062941B (zh) * 2015-08-25 2019-03-05 江南大学 一种利用重组枯草芽孢杆菌全细胞转化生产l-鸟氨酸的方法
WO2017050240A1 (en) * 2015-09-21 2017-03-30 Bio-Cancer Treatment International Ltd. Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
CN105112391B (zh) * 2015-09-22 2018-07-06 浙江道尔生物科技有限公司 一种人源精氨酸酶突变体及其制备方法和用途
ES2909556T3 (es) 2016-08-08 2022-05-09 Aerase Inc Composiciones y procedimientos para el tratamiento de cáncer con agentes de disminución de arginina y de inmunoncología
EP3720476A1 (de) 2017-12-05 2020-10-14 AERase, Inc. Verfahren und zusammensetzung zur behandlung von arginase-1-mangel
US20200181597A1 (en) * 2018-05-31 2020-06-11 The Hong Kong Polytechnic University Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities
US20210162028A1 (en) * 2019-12-02 2021-06-03 The Hong Kong Polytechnic University Methods for Inducing Intermittent Fasting and Modulating Autophagy
CN115804845A (zh) * 2022-12-02 2023-03-17 华东理工大学 精氨酸剥夺在延缓衰老与联合化疗药物***中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US5851985A (en) * 1996-08-16 1998-12-22 Tepic; Slobodan Treatment of tumors by arginine deprivation
WO1998024473A1 (fr) * 1996-12-03 1998-06-11 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de fibrose des tissus
AU3305999A (en) 1998-02-26 1999-09-15 Beth Israel Deaconess Medical Center Amino acid degrading enzymes modulate cell death
US6413757B1 (en) * 2000-02-28 2002-07-02 Millennium Pharmaceuticals, Inc. 25312, a novel human agmatinase-like homolog
CN1324945A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——精氨酸酶12和编码这种多肽的多核苷酸
CN1324942A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶9和编码这种多肽的多核苷酸
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
DE10047204A1 (de) 2000-09-23 2002-04-25 Henkel Kgaa Topische Hautbehandlungsmittel mit Arginase
CN1345966A (zh) * 2000-09-26 2002-04-24 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶35.42和编码这种多肽的多核苷酸
CN1345970A (zh) * 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——含精氨酸酶结构域的蛋白质9.35和编码这种多肽的多核苷酸
AU2001289132A1 (en) 2000-11-28 2002-06-11 Phoenix Pharmacologics, Inc. Modified arginine deiminase
WO2003063780A2 (en) 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion

Also Published As

Publication number Publication date
NZ537774A (en) 2007-01-26
CN1918298A (zh) 2007-02-21
JP5307042B2 (ja) 2013-10-02
CN1918298B (zh) 2011-06-29
HK1071687A1 (en) 2005-07-29
HK1053577A2 (en) 2003-10-10
EP1517699B1 (de) 2008-02-13
IL165858A (en) 2010-12-30
US20080226617A1 (en) 2008-09-18
EP1517699A1 (de) 2005-03-30
DE60319083T2 (de) 2009-02-05
MXPA04012970A (es) 2005-08-18
IL165858A0 (en) 2006-01-15
JP2013172743A (ja) 2013-09-05
US8679810B2 (en) 2014-03-25
US20090123450A1 (en) 2009-05-14
AU2002325782A1 (en) 2004-01-06
WO2004001048A1 (en) 2003-12-31
ATE385807T1 (de) 2008-03-15
CN101433714A (zh) 2009-05-20
DE60319083D1 (de) 2008-03-27
HK1109876A1 (en) 2008-06-27
ATE461707T1 (de) 2010-04-15
US20080248018A1 (en) 2008-10-09
JP2010148509A (ja) 2010-07-08
US7951366B2 (en) 2011-05-31
US20050244398A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
HK1109876A1 (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
RU2006145899A (ru) Ферменты для фармацевтического применения
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
DE60330485D1 (de) Zur behandlung von diabetes
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE312635T1 (de) Ventilanordnung
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
ATE507838T1 (de) Verwendung von dipeptidylpeptidase iv und aminopeptidase-n inhibitoren zur behandlung von ischämie-induzierter neurodegeneration
DE69427127D1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
ATE350374T1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EA200500782A1 (ru) Лечение геморрагического шока
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
ATE253117T1 (de) Adenovirus e4 proteine für induktion von zelltod
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension

Legal Events

Date Code Title Description
8364 No opposition during term of opposition